… ibogaine as a drug therapy. W. Bryan Hubbard, executive director of the American Ibogaine Initiative, who's been pushing state governments to …
Delegates From 15 States Meet in Aspen to Forge National Strategy Around Ibogaine Clinical Research
The Ohio State University Launches First Global Survey to Study Ibogaine Treatment Outcomes
Ibogaine, a naturally occurring psychoactive substance derived from the root bark of the Tabernanthe iboga plant native to Central Africa, has …
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs
Toronto-based Psyence Biomedical Ltd (NASDAQ: PBM) just invested US$500,000 into the private South African drug developer PsyLabs. The capital injection follows Psyence taking an 11 per cent stake in the natural psychedelics company in September.
PsyLabs is federally licensed to produce psilocybin, psilocin, mescaline, DMT and ibogaine for international research partners at its facility in Cape Town. It has been in operation for four years. The extraction ...
Psyence BioMed Deepens Psychedelic Supply Chain With $500K PsyLabs Investment And …
Ibogaine, a psychoactive compound extracted from the African Tabernanthe iboga plant, has gained attention for its potential to disrupt addictive …